Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting.
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting.
复制标题
DOI：
10.3390/cells10071685
复制
发表时间：
2021-07-03
期刊：
影响因子：
6
通讯作者：
Tinari N
中科院分区：
文献类型：
--
作者：
Grassadonia A;Graziano V;Iezzi L;Vici P;Barba M;Pizzuti L;Cicero G;Krasniqi E;Mazzotta M;Marinelli D;Amodio A;Natoli C;Tinari N
中性粒细胞与淋巴细胞比率（NLR）是一个很有前途的预测和预后因素在乳腺癌。我们研究了其预测接受新辅助化疗（NACT）的管腔A或管腔B-HER 2阴性乳腺癌患者的无病生存期（DFS）和总生存期（OS）的能力。对168例连续管腔型乳腺癌患者的治疗前全血细胞计数进行了评价，以评估NLR。根据通过接受工作曲线（ROC）分析确定的临界值，将研究人群分层为NLR低或NLR高。还收集了其他治疗前和治疗后临床病理学特征的数据。采用Kaplan-Meier曲线、对数秩检验和考克斯比例风险模型进行统计分析。与NLR高患者相比，治疗前NLR低患者的DFS（HR：6.97，95% CI：1.65-10.55，p = 0.002）和OS（HR：7.79，95% CI：1.25-15.07，p = 0.021）显著缩短。非导管组织学、管腔B亚型和治疗后Ki 67 ≥ 14%也与DFS恶化相关（分别为p = 0.016、p = 0.002和p = 0.001）。在多变量分析中，管腔型B亚型、治疗后Ki 67 ≥ 14%和NLR低仍然是DFS的独立预后因素，而只有治疗后Ki 67 ≥ 14%和NLR低影响OS。本研究提供的证据表明，治疗前NLR低有助于识别接受NACT治疗的管腔型乳腺癌患者中复发和死亡风险较高的女性。
The neutrophil to lymphocyte ratio (NLR) is a promising predictive and prognostic factor in breast cancer. We investigated its ability to predict disease-free survival (DFS) and overall survival (OS) in patients with luminal A- or luminal B-HER2-negative breast cancer who received neoadjuvant chemotherapy (NACT). Pre-treatment complete blood cell counts from 168 consecutive patients with luminal breast cancer were evaluated to assess NLR. The study population was stratified into NLRlow or NLRhigh according to a cut-off value established by receiving operator curve (ROC) analysis. Data on additional pre- and post-treatment clinical-pathological characteristics were also collected. Kaplan–Meier curves, log-rank tests, and Cox proportional hazards models were used for statistical analyses. Patients with pre-treatment NLRlow showed a significantly shorter DFS (HR: 6.97, 95% CI: 1.65–10.55, p = 0.002) and OS (HR: 7.79, 95% CI: 1.25–15.07, p = 0.021) compared to those with NLRhigh. Non-ductal histology, luminal B subtype, and post-treatment Ki67 ≥ 14% were also associated with worse DFS (p = 0.016, p = 0.002, and p = 0.001, respectively). In a multivariate analysis, luminal B subtype, post-treatment Ki67 ≥ 14%, and NLRlow remained independent prognostic factors for DFS, while only post-treatment Ki67 ≥ 14% and NLRlow affected OS. The present study provides evidence that pre-treatment NLRlow helps identify women at higher risk of recurrence and death among patients affected by luminal breast cancer treated with NACT.
登录
查看更多内容
影响因子：
3.7
作者：
Asano Y;Kashiwagi S;Onoda N;Noda S;Kawajiri H;Takashima T;Ohsawa M;Kitagawa S;Hirakawa K
通讯作者：
Hirakawa K
影响因子：
7.3
作者：
Goldberg J;Pastorello RG;Vallius T;Davis J;Cui YX;Agudo J;Waks AG;Keenan T;McAllister SS;Tolaney SM;Mittendorf EA;Guerriero JL
通讯作者：
Guerriero JL
影响因子：
2.6
作者：
Chae, S.;Kang, K. M.;Kim, E. K.
通讯作者：
Kim, E. K.
影响因子：
51.1
作者：
Denkert, Carsten;von Minckwitz, Gunter;Loibl, Sibylle
通讯作者：
Loibl, Sibylle
影响因子：
3.6
作者：
Angelucci, Domenico;Tinari, Nicola;Grassadonia, Antonino;Cianchetti, Ettore;Ausili-Cefaro, Giampiero;Iezzi, Laura;Zilli, Marinella;Grossi, Simona;Ursini, Lucia Anna;Scognamiglio, Maria Teresa;Castrilli, Graziella;De Tursi, Michele;Noccioli, Paolo;Cioy, Pasquale;Iacobelli, Stefano;Natoli, Clara
通讯作者：
Natoli, Clara